This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The greatly weakened Czechoslovak Republic was forced to grant major concessions to the non-Czechs. The executive committee of the Slovak People's Party met at Žilina on 5 October 1938, and with the acquiescence of all Slovak parties except the Social Democrats formed an autonomous Slovak government under Jozef Tiso. Similarly, the two major factions in Subcarpathian Ruthenia, the Russophiles and Ukrainophiles, agreed on the establishment of an autonomous government, which was constituted on 8 October. Reflecting the spread of modern Ukrainian national consciousness, the pro-Ukrainian faction, led by Avhustyn Voloshyn, gained control of the local government and Subcarpathian Ruthenia was renamed Carpatho-Ukraine. In 1939, during the occupation, the Nazis banned Russian ballet. A last-ditch attempt to save Czechoslovakia from total ruin was made by the British and French governments, who on 27 January 1939, concluded an agreement of financial assistance with the Czechoslovak government. In this agreement, the British and French governments undertook to lend the Czechoslovak government £8 million and make a gift of £4 million. Part of the funds were allocated to help resettle Czechs and Slovaks who had fled from territories lost to Germany, Hungary, and Poland in the Munich Agreement or the Vienna Arbitration Award.
== Chemical properties == Bromo(I) fluorosulfonate is a blackish-red, viscous, hydrolysis-sensitive liquid that reacts violently with water. Upon cooling, it solidifies into a glassy state. Bromo(I) fluorosulfonate reacts with iodine(I) fluorosulfonate at temperatures above 50 °C to form dibromoiodofluorosulfonate:
Cheese consists of proteins and fat from milk, usually the milk of cows, buffalo, goats, or sheep. It is produced by coagulation that is caused by destabilization of the casein micelle, which begins the processes of fractionation and selective concentration. Typically, the milk is acidified and then coagulated by the addition of rennet, containing a proteolytic enzyme known as rennin; traditionally obtained from the stomachs of calves, but currently produced more often from genetically modified microorganisms. The solids are then separated and pressed into final form. Unlike many proteins, casein is not coagulated by heat. During the process of clotting, milk-clotting proteases act on the soluble portion of the caseins, κ-casein, thus originating an unstable micellar state that results in clot formation. When coagulated with chymosin, casein is sometimes called paracasein. Chymosin (EC 3.4.23.4) is an aspartic protease that specifically hydrolyzes the peptide bond in Phe105-Met106 of κ-casein, and is considered to be the most efficient protease for the cheese-making industry (Rao et al., 1998). British terminology, on the other hand, uses the term caseinogen for the uncoagulated protein and casein for the coagulated protein. As it exists in milk, it is a salt of calcium.
Sources: en.wikipedia.org
=== Instrument Calibration and Quality Control === All refractive index detectors require calibration upon first setting up the instrument as well as periodic quality control. Most manufacturer's recommend calibration with pure water and a sucrose calibration solution of a known refractive index. Once the instrument is in calibration mode, the pure water acts as a zero baseline reading, while the sucrose solution compares its known RI to the output, and the machine is adjusted accordingly. After the pump has not been used for a while, it is necessary to purge the tubes of any contaminant air that has diffused into the channels. This is typically accomplished with isopropyl alcohol.
Senate Minority Leader Chuck Schumer criticized the investigation for undermining the Federal Reserve's independence and suggested that the investigation was being done to make Powell a scapegoat for public disapproval of Trump's handling of the U.S. economy and the administration's trade policies. After Trump announced that he would nominate Warsh to replace Powell on January 30, Tillis stated that he will oppose Warsh's nomination until the investigation into Powell is "fully and transparently resolved." Since the Senate Banking Committee's composition currently includes 13 Republicans and 11 Democrats, Tillis has the ability to block the committee from voting to advance Warsh's nomination to a full Senate confirmation vote. John Thune has said that Warsh will "probably not" be confirmed without support from Tillis. On February 4, Tillis, who is not seeking reelection in 2026, subsequently said that he will block Warsh's nomination for the remainder of the 119th United States Congress if the investigation continues until his term expires in January 2027, while the day before, Senate Democrats sitting on the Banking Committee called for a delay to the nomination until both the Powell investigation and the investigation of Lisa Cook were both ended. Tillis stated the previous September that he would not consider any replacement for Cook until the litigation was resolved.
The properties of quantum dots can be also tuned by the synthetic scheme, high temperature solvent/ligand mixtures that influence the nanocrystal properties. High-quality QD contrast agents are obtained at elevated temperatures; however, because they have lower water solubility, their usage as cell markers is limited. Further functionalization with hydrophilic ligands is required. The advantages of QD are represented by their fast action; they are able to label a target tissue or cell in seconds. In vivo studies show that QD are able to selectively label cancer cells, and they accumulate at tumor sites. Tumor cells labeled with QD can be tracked with multiphoton microscopy as they invade lung tissue. In both studies, spectral imaging and autofluorescent subtraction allowed multicolour in vivo visualization of cells and tissues. A major drawback of QD is their relatively high toxicity. Functionalizations with different substrates that increase bioaffinity and decrease toxicity are in progress. For instance, sulfur from the QD shell is able to form reversible disulfide bonds with a wide class of organic compounds.
Isolated cataplexy unto itself (i.e., in the absence of characteristically associated narcolepsy), admittedly a rare condition There is anecdotal and tentative, as-yet-undocumented information suggesting that clomipramine may address certain core features of hyperacusis, and possibly misophonia. In the case of hyperacusis, this appears to be especially the case at doses > 150 mg/d. As-with obsessive-compulsive disorder, a full response to any one dose may not be experienced for up to 12–16 weeks. Although lithium is most-associated with the treatment of bipolar disorder (where it is known for its general mood-stabilising features and to be especially useful in treating and preventing mania), it may have a certain place in the management of treatment-resistant depression (which is often of higher severity than other depressions which have not been addressed with ECT). In these cases it is often prescribed alongside SSRIs (e.g., fluoxetine, paroxetine), venlafaxine and various of the tricyclics (e.g., clomipramine, amitriptyline, nortriptyline, maprotiline), which is why it may feature sometimes in the discussion of depression being managed with clomipramine. Lithium also significantly reduces the long-term risk of suicide in general. In any case, it is not necessary to have a diagnosis of bipolar affective disorder (manic-depressive illness), or even to be considered to have subtle elements of it ("soft bipolarity"), to benefit from lithium in the context of treatment with clomipramine.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.